Press Releases

Date Title and Summary Additional Formats
Toggle Summary Anthera Pharmaceuticals, Inc. Appoints Donald Santel to Board of Directors View HTML
Toggle Summary Anthera Announces Positive Phase Ii Clinical Results From A-002 Cardiovascular Disease Trial View HTML
Toggle Summary Anthera Announces Completion of Enrollment and Dosing In Phase II Trial of A-002 for the Treatment of Cardiovascular Disease View HTML
Toggle Summary Anthera Completes Enrollment of "Plasma" Trial with A-002 and Announces Initiation of New Investigator Study View HTML
Toggle Summary First Patient Enrolled In Phase 2 "Plasma" Trial with A-002 For Patients with Coronary Atherosclerosis View HTML
Toggle Summary Anthera Pharmaceuticals, Inc. Announces Appointment of Dr. James Pennington as Executive Vice President & Chief Medical Officer View HTML
Toggle Summary Anthera Pharmaceuticals, Inc. Announces Formation of Clinical Advisory Board for Respiratory and Acute Care Programs View HTML
Toggle Summary Anthera pharmaceuticals' Inc. announces formation of clinical advisory board for cardiovascular program View HTML
Toggle Summary Dr. David D. Waters Joins Anthera Pharmaceuticals As Cardiovascular Research Fellow View HTML
Toggle Summary Anthera Receives IND Approval from FDA to begin phase 2 "IMPACTS" trial with A-001 for prevention of acute chest syndrome in patients with sickle cell disease View HTML